 DUBLIN, Ireland, Dec. 04, 2020 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA, a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in connection with hiring two new employees, the compensation committee of the Companys board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 90,000 ordinary shares of the Company. The options have an exercise price per share equal to 11.00, which was the closing trading price on December 1, 2020, the date of the grants. The inducement awards will vest over four years, with 25 of the underlying shares vesting on the one-year anniversary of the date of grants and 148th of the underlying shares vesting monthly thereafter over 36 months. The options were granted pursuant to the Companys 2020 Employment Inducement Incentive Plan, which was approved by the Companys board of directors under Rule 5635c4 of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. 